» Articles » PMID: 29702232

Biopharmaceutical Evaluation of Surface Active Ophthalmic Excipients Using in Vitro and Ex Vivo Corneal Models

Overview
Journal Eur J Pharm Sci
Specialties Chemistry
Pharmacology
Date 2018 Apr 28
PMID 29702232
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to systematically investigate the effects of surface active ophthalmic excipients on the corneal permeation of ophthalmic drugs using in vitro (HCE-T cell-based model) and ex vivo (freshly excised porcine cornea) models. The permeation of four ophthalmic drugs (i.e., timolol maleate, chloramphenicol, diclofenac sodium and dexamethasone) across in vitro and ex vivo corneal models was evaluated in the absence and presence of four commonly used surface active ophthalmic excipients (i.e., Polysorbate 80, Tyloxapol, Cremophor® EL and Pluronic® F68). The concentration and self-aggregation-dependent effects of surface active ophthalmic excipients on ophthalmic drug permeability were studied from the concentration region where only dissolved monomer molecules of surface active ophthalmic excipients exist, as well as the concentration region in which aggregates of variable size and dispersion are spontaneously formed. Neither the surface active ophthalmic excipients nor the ophthalmic drugs at all concentrations that were tested significantly affected the barrier properties of both corneal models, as assessed by transepithelial electrical resistance (TEER) monitoring during the permeability experiments. The lowest concentration of all investigated surface active ophthalmic excipients did not significantly affect the ophthalmic drug permeability across both of the corneal models that were used. For three ophthalmic drugs (i.e., chloramphenicol, diclofenac sodium and dexamethasone), depressed in vitro and ex vivo permeability were observed in the concentration range of either Polysorbate 80, Tyloxapol, Cremophor® EL or Pluronic® F68, at which self-aggregation is detected. The effect was the most pronounced for Cremophor® EL (1 and 2%, w/V) and was the least pronounced for Pluronic® F68 (1%, w/V). However, all surface active ophthalmic excipients over the entire concentration range that was tested did not significantly affect the in vitro and ex vivo permeability of timolol maleate, which is the most hydrophilic ophthalmic drug that was investigated. The results of the dynamic light scattering measurements point to the association of ophthalmic drugs with self-aggregates of surface active ophthalmic excipients as the potential mechanism of the observed permeability-depressing effect of surface active ophthalmic excipients. A strong and statistically significant correlation was observed between in vitro and ex vivo permeability of ophthalmic drugs in the presence of surface active ophthalmic excipients, which indicates that the observed permeability-altering effects of surface active ophthalmic excipients were comparable and were mediated by the same mechanism in both corneal models.

Citing Articles

Design and validation of a custom-made system to measure transepithelial electrical impedance in human corneas preserved in active storage machine.

Mentek M, Peyret B, Zouari S, Urbaniak S, Papillon J, Crouzet E Int J Pharm X. 2024; 7:100234.

PMID: 38374874 PMC: 10875219. DOI: 10.1016/j.ijpx.2024.100234.


Dynamic Ex Vivo Porcine Eye Model to Measure Ophthalmic Drug Penetration under Simulated Lacrimal Flow.

Barbalho G, Falcao M, Lopes J, Lopes J, Contarato J, Gelfuso G Pharmaceutics. 2023; 15(9).

PMID: 37765293 PMC: 10534681. DOI: 10.3390/pharmaceutics15092325.


Nanostructured Lipid Carriers for Enhanced Transscleral Delivery of Dexamethasone Acetate: Development, Ex Vivo Characterization and Multiphoton Microscopy Studies.

Gonzalez-Fernandez F, Delledonne A, Nicoli S, Gasco P, Padula C, Santi P Pharmaceutics. 2023; 15(2).

PMID: 36839729 PMC: 9961953. DOI: 10.3390/pharmaceutics15020407.


Fluorescent Nanosystems for Drug Tracking and Theranostics: Recent Applications in the Ocular Field.

Zingale E, Romeo A, Rizzo S, Cimino C, Bonaccorso A, Carbone C Pharmaceutics. 2022; 14(5).

PMID: 35631540 PMC: 9147643. DOI: 10.3390/pharmaceutics14050955.


SCD1-Fatty Acid Desaturase Inhibitor MF-438 Alleviates Latent Inflammation Induced by Preservative-Free Prostaglandin Analog Eye Drops.

Pacwa A, Machowicz J, Wojtyniak A, Pietrucha-Dutczak M, Toropainen E, Koskela A J Inflamm Res. 2022; 15:793-806.

PMID: 35173454 PMC: 8840838. DOI: 10.2147/JIR.S347784.